Search the Newsreel

ABVC BIOPHARMA, INC. Q2 2026: Revenue $0 EPS $(0.03) — 10-Q Summary

ABVC BIOPHARMA, INC. reported its second-quarter 2026 results, showing no revenue but a significantly narrower net loss compared to the previous year. The company posted a net loss of $736,934, an improvement from a $2,257,022 loss in Q2 2025, and diluted earnings per share …

Connect Biopharma (CNTB) widens Q2 2026 loss as R&D rises, cash at $31.5M

Connect Biopharma reported a wider net loss of $17.3 million for Q2 2026, compared to $12.9 million in Q2 2025, primarily due to increased research and development expenses. Despite the loss, license and collaboration revenues surged to $2.8 million, driven by a Simcere milestone …

Connect Biopharma (CNTB) ramps rademikibart spend as losses deepen in 2026

Connect Biopharma Holdings Limited (CNTB) reported increased R&D expenses and wider net losses for the three and six months ended June 30, 2026, primarily due to expanded clinical programs for rademikibart in asthma and COPD. Despite higher collaboration revenue from a Simcere partnership, the …

ABVC BioPharma (ABVC) flags going concern risk after Q2 2026 cash drain

ArriVent Expects Firmonertinib Lung Cancer Trial Data in 2H 2026

ArriVent BioPharma (AVBP) reported its Q2 2026 financial results, including $373.1 million in cash and investments, projected to fund operations into 2028. The company anticipates topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC in the second …

Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing

Morgan Stanley and Morgan Stanley Investment Management Inc. have disclosed significant beneficial ownership in Arbutus Biopharma Corp (ABUS) common shares through a Schedule 13G/A filing. As of June 30, 2026, Morgan Stanley reporting units beneficially own 8.8% of Arbutus Biopharma's common shares, while Morgan …

Why is Sutro Biopharma Stock Falling On Wednesday?

Sutro Biopharma (NASDAQ: STRO) stock is falling due to challenges following an update on its STRO-004 Phase 1 study, despite reporting early clinical activity. The company noted dose-limiting toxicities only at the highest dose, leading to dose reduction. Analysts generally have a "Buy" rating …

Sutro Biopharma (NASDAQ:STRO) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Sutro Biopharma (NASDAQ:STRO) reported quarterly earnings that missed analysts' expectations, with a loss of $2.33 per share against an anticipated $2.19 loss and revenues of $9.84 million versus a forecast of $11.96 million. Following the announcement, the company's shares declined significantly. Despite the miss, …

Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price

Wedbush has increased its price target for Vor Biopharma (NASDAQ:VOR) to $27 from $18, while maintaining a neutral rating, suggesting a potential 21% upside. Despite this positive target, the company missed its recent quarterly earnings estimates, reporting a loss of $0.80 per share against …

VOR Maintains Rating by Wedbush -- Price Target Raised to $27.00

Wedbush has maintained its Neutral rating on Vor Biopharma (VOR) but significantly increased its price target from $18.00 to $27.00, suggesting potential for growth despite a cautious outlook. The company, a clinical-stage biopharmaceutical firm focusing on autoimmune diseases, has a low GF Score™ of …

Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Arbutus Biopharma (NASDAQ:ABUS) reported a quarterly loss of $0.03 per share, missing analyst expectations by $0.01. Despite the earnings miss, the company's revenue of $1.01 million surpassed the consensus estimate of $0.70 million. Following the announcement, ABUS shares declined by 3.0% to $4.53, while …

Adage Capital reports 1.54M Karyopharm (KPTI) shares, a 6.78% stake

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has reported a beneficial ownership of 1,536,736 shares of Karyopharm Therapeutics Inc. (KPTI) common stock, representing a 6.78% stake. This includes 15,414 shares issuable upon the exercise of warrants. The filing indicates shared …

Arbutus Biopharma earnings matched, revenue topped estimates

Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings

Vor Biopharma (NASDAQ:VOR) experienced a 6.5% drop in stock price following an earnings announcement where the company reported a quarterly EPS of negative $0.80, missing the consensus estimate of negative $0.69. Despite the disappointing earnings and reduced trading volume, the company maintains a "Moderate …

Form 8K Sutro Biopharma For: 12 August By Investing.com

The article reports that Sutro Biopharma filed a Form 8K on August 12. It provides no further details on the content of the filing but mentions the stock symbol STRO, which was down 1.62%. The rest of the content includes market data, news headlines, …

Sutro Biopharma Announces Q2 2026 Financial Results and Updates Corporate Presentation

Sutro Biopharma, Inc. has announced its financial results for the second quarter ended June 30, 2026, and released an updated corporate presentation. These disclosures were made via a current report filed with the SEC, which included a press release detailing the quarterly performance and …

Arbutus Biopharma Announces Q2 2026 Financial Results Highlighting Genevant License Revenue Impact

Arbutus Biopharma Corporation reported its Q2 2026 financial results, showcasing a significant net income of $164,552 thousand for the six months ending June 30, 2026, primarily due to $179,373 thousand in license revenue from Genevant. This marks a substantial improvement from a net loss …

COSCIENS Biopharma Stock Builds Positive Momentum as Q2 Efficiency Gains Strengthen TSX:CSCI Outlook

Sutro Biopharma earnings missed by $0.13, revenue fell short of estimates

UBS raises ConocoPhillips stock price target on strong project pipeline

UBS has increased its price target for ConocoPhillips (NYSE:COP) to $153 from $143, maintaining a Buy rating, citing the company's strong project pipeline and positive second-quarter update despite CEO transition concerns. The analyst firm noted the company's robust cash flow growth outlook and improved …

What's Next for Arbutus Biopharma Corp (ABUS) After Q2 Earnings

Arbutus Biopharma Corp 2026: Revenue $1.01M, EPS ($0.03) — 10-Q Summary

Arbutus Biopharma Corp reported its Q2 2026 results with revenue of $1.01M and a net loss of ($5.14M), a significant decrease from the prior year's $10.74M revenue and $2.52M net income. The diluted EPS was ($0.03) compared to $0.01 a year earlier. Key business …

Earnings Flash (ABUS) Arbutus Biopharma Posts Q2 Loss $0.03 a Share, vs. FactSet Est of $0.02 Loss

Arbutus: Q2 Earnings Snapshot

Arbutus Biopharma (ABUS) swings to $164.6M H1 profit on $178.4M Moderna payout

Sutro Biopharma (STRO) revenue drops as cash rises after $110M stock sale

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Biopharma Corporation Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus …

Sutro Biopharma Reports $9.8 Million Revenue in Q2 2026

Sutro Biopharma GAAP EPS of -$2.33 misses by $0.14, revenue of $9.84M misses by $1.2M

* Sutro Biopharma press release [https://seekingalpha.com/pr/20616182-sutro-biopharma-reports-second-quarter-2026-financial-results-and-provides-early-update-on] (STRO [https://seekingalpha.com/symbol/STRO]): Q2 GAAP EPS of -$2.33 misses by $0.14. * Revenue of $9.84M (-84.6% Y/Y) misses by $1.2M. MORE ON SUTRO BIOPHARMA * Seeking Alpha’s Quant Rating on Sutro Biopharma [https://seekingalpha.com/symbol/STRO/ratings/quant-ratings] * Historical earnings data for Sutro …

ConocoPhillips (NYSE:COP) Stock Rating Upgraded by Freedom Capital

Freedom Capital has upgraded ConocoPhillips (NYSE:COP) stock from "hold" to "strong buy," contributing to a generally positive analyst outlook. The company recently reported strong quarterly results, with EPS of $3.24 and revenue of $19.52 billion, surpassing estimates, and institutional investors own 82.36% of the …

Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright

HC Wainwright has lowered its Q3 2026 EPS estimate for Immix Biopharma (NASDAQ:IMMX) to a loss of $0.17 per share, down from a previous forecast of $0.14 loss, while maintaining a "Buy" rating and a $25 price target. This revision follows Immix Biopharma reporting …

Earnings Flash (CSCI.TO) COSCIENS Biopharma Inc. Reports Q2 Revenue $3.1M

Will COSCIENS Biopharma Inc. (CSCI) Beat Estimates Again in Its Next Earnings Report?

The Top 5 Analyst Questions From ConocoPhillips’s Q2 Earnings Call

ConocoPhillips (COP) PT Raised to $153 at UBS

UBS analyst Josh Silverstein has increased the price target for ConocoPhillips (NYSE: COP) to $153.00 from $143.00. The firm is maintaining a Buy rating on the stock. This update is part of a premium article on StreetInsider.com.

Theravance Biopharma (TBPH) Stock Caught Between Fading Gains And Royalty Doubts